With the continuous development of biopharmaceuticals in Asia, it is no longer a mere manufacturing, but a turn to trial and research and development. For many countries on this continent, leaders have spent a lot of time and energy to promote innovation. At the same time, regions outside Asia are also paying close attention as Asia is seeking growth outside of traditional markets such as the US and Europe. Recently, the GEN website summarized eight clusters of the Asian biopharmaceutical market, while China ranked first. 1. China China is not only the most populous country in the world, but also a leader in biopharmaceuticals in Asia, with R&D expenditures ($33.6 billion in 2013), number of companies (7,500 in 2013) and positions (250,000 in 2013). Beyond other countries in Asia. In terms of the number of patents, China ranked third with 30,627, and beat Japan with a slight advantage on the IPO (18 companies listed, raising 2.7 billion). GEN expects that with the release of the 13th Five-Year Plan (2016-2020), more information on biotechnology and the ambitious goals of growth and innovation are expected next year. 2. Japan Japan is far ahead of other Asian countries (154,918) in terms of the number of patents, reflecting traditional medical activities as well as university and institutional research. But it lost to China on a weak margin on the IPO, and nine companies raised $2.6 billion. Japan ranks second in Asia in terms of R&D spending ($160.2 billion in 2013) and number of companies (552 in 2013). 3. India India ranks fourth in Asia for R&D spending ($40 billion in 2014), fourth in IPO ($80 million in Claris Lifesciences in 2010), number of patents (18,447) and number of companies (more than 400) ) are ranked fifth. Employment in the biopharmaceutical industry has changed dramatically, from 50,000 in 2013 to 450,000 this year. 4. South Korea South Korea ranks top in Asia in terms of the number of patents (18,620), research and development expenditures ($68.9 billion in 2013) and the number of companies (853). Since Seegene raised $17.5 million in 2010, South Korea has not yet completed an IPO for biopharmaceutical companies. However, this is expected to change this year as stem cell biotechnology company Corestem is preparing to go public and raise 30 billion won (about 26.5 million US dollars). 5. Taiwan Although Taiwan ranks seventh in Asia in terms of patents (8,221) and sixth in research and development spending ($30.3 billion in 2013), biopharmaceutical companies continue to increase (to 350 pharmaceutical companies and 490 applied organisms) Technology companies ranked fourth, and IPO ranked fourth (four companies raised $204 million). A total of 71,580 people work in biopharmaceuticals. The most successful local company is Medigen, with a market capitalization of more than $2 billion. Since then, Australia, Malaysia and Singapore have ranked 6-8 respectively. Foot Protective Shoes,Leather Safety Shoes,Smash Proof Work Shoes,High Cut Safety Boots Dongying Hong Xing Labor Protection Products Co.,Ltd. , https://www.hongxinglabor.com